REGN
Regeneron Pharmaceuticals, Inc.
Price Chart
Latest Quote
$635.45
+6.72 (+1.07%)
Current Price
| Previous Close | $628.73 |
| Open | $632.26 |
| Day High | $640.82 |
| Day Low | $632.09 |
| Volume | 975,513 |
Stock Information
| Quarterly Dividend / Yield | $3.76 / 0.60% |
| Shares Outstanding | 103.02M |
| Quarterly Dividend Yield | 0.60% |
| Quarterly Dividend | $3.76 |
| Total Debt | $2.71B |
| Cash Equivalents | $8.75B |
| Revenue | $14.92B |
| Net Income | $4.42B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $66.62B |
| P/E Ratio | 15.53 |
| EPS (TTM) | $40.93 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $57.92B |
| Sales | $14.92B |
| Income | $4.42B |
| Book/sh | $308.32 |
| Cash/sh | $84.97 |
| Employees | 15K |
Financial Ratios
| Quick Ratio | 2.84 |
| Current Ratio | 3.56 |
| Debt/Eq | 8.61 |
| EPS Growth TTM | -10.10% |
Returns & Margins
| ROA | 6.13% |
| ROE | 14.55% |
| Gross Margin | 43.89% |
| Operating Margin | 20.66% |
| Profit Margin | 29.65% |
Ownership
| Insider Ownership | 2.03% |
| Institutional Ownership | 92.18% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 11.82 |
| PEG | 1.05 |
| P/S | 4.47 |
| P/B | 2.06 |
Analyst Data
| Recommendation | buy |
| Target Price | $833.31 |
Technical Indicators
| SMA20 | $652.52 |
| SMA50 | $706.29 |
| SMA200 | $694.15 |
| RSI | 32.19 |
| ATR | 20.8631 |
| Shares Float | 97.67M |
| Short Float | 2.80% |
| Short Ratio | 3.55 |
| Volatility | 0.24 |
| Rel Volume | 0.81 |
Performance History
| Week | +3.36% |
| Month | -11.74% |
| Quarter | -16.25% |
| 6 Months | -11.95% |
| YTD | -17.92% |
| Year | +31.76% |
| 3 Years | -12.90% |
| 5 Years | +27.52% |
| 10 Years | +58.63% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $635.45 | 975,513 |
| 2026-06-04 | $628.73 | 974,700 |
| 2026-06-03 | $618.95 | 986,700 |
| 2026-06-02 | $602.92 | 1,066,700 |
| 2026-06-01 | $600.66 | 1,079,900 |
| 2026-05-29 | $614.78 | 2,187,500 |
| 2026-05-28 | $621.52 | 1,234,400 |
| 2026-05-27 | $627.74 | 1,913,500 |
| 2026-05-26 | $634.62 | 889,800 |
| 2026-05-22 | $638.88 | 994,900 |
| 2026-05-21 | $642.59 | 1,178,500 |
| 2026-05-20 | $649.76 | 1,165,600 |
| 2026-05-19 | $629.36 | 1,445,100 |
| 2026-05-18 | $628.74 | 2,996,600 |
| 2026-05-15 | $697.21 | 728,000 |
| 2026-05-14 | $711.81 | 767,200 |
| 2026-05-13 | $718.81 | 879,300 |
| 2026-05-12 | $722.33 | 824,300 |
| 2026-05-11 | $711.71 | 1,227,200 |
| 2026-05-08 | $713.82 | 589,000 |
| 2026-05-07 | $708.04 | 774,600 |
| 2026-05-06 | $719.97 | 739,900 |
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
đ° Latest News
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
Simply Wall St. âĸ 2026-06-05T18:22:06Z
Parabilis eyes $475m IPO to push lead asset into Phase III
Pharmaceutical Technology âĸ 2026-06-05T10:54:41Z
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
Zacks âĸ 2026-06-04T17:25:00Z
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
Zacks âĸ 2026-06-04T13:10:00Z
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
Pharmaceutical Technology âĸ 2026-06-04T09:21:36Z
Why Regeneron (REGN) Stock Is Trading Up Today
StockStory âĸ 2026-06-04T00:31:33Z
How Investors May Respond To Regeneron (REGN) EMA Fast-Track Review Of Otarmeni Gene Therapy
Simply Wall St. âĸ 2026-06-03T22:06:17Z
2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky
StockStory âĸ 2026-06-03T15:19:33Z
NewLimitâs $435M megaround; Lillyâs busy dealmaking week
BioPharma Dive âĸ 2026-06-03T11:15:00Z
Are Options Traders Betting on a Big Move in Regeneron Stock?
Zacks âĸ 2026-06-02T13:25:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,100,700,000 | $1,970,500,000 | $1,815,800,000 | $1,560,400,000 |
| Cost Of Revenue | $2,100,700,000 | $1,970,500,000 | $1,815,800,000 | $1,560,400,000 |
| Total Revenue | $14,342,900,000 | $14,202,000,000 | $13,117,200,000 | $12,172,900,000 |
| Operating Revenue | $13,640,300,000 | $13,687,000,000 | $12,581,100,000 | $11,807,800,000 |
| Expenses | ||||
| Interest Expense | $43,800,000 | $55,200,000 | $73,000,000 | $59,400,000 |
| Total Expenses | $10,640,900,000 | $10,211,300,000 | $9,070,100,000 | $7,434,000,000 |
| Other Income Expense | $855,700,000 | $133,000,000 | $-270,700,000 | $19,200,000 |
| Other Non Operating Income Expenses | $33,700,000 | $14,700,000 | $-4,300,000 | $8,800,000 |
| Net Non Operating Interest Income Expense | $673,000,000 | $656,200,000 | $422,900,000 | $100,700,000 |
| Interest Expense Non Operating | $43,800,000 | $55,200,000 | $73,000,000 | $59,400,000 |
| Operating Expense | $8,540,200,000 | $8,240,800,000 | $7,254,300,000 | $5,873,600,000 |
| Other Operating Expenses | $-10,000,000 | $53,400,000 | $-2,100,000 | $-89,900,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $4,504,900,000 | $4,412,600,000 | $3,953,600,000 | $4,338,400,000 |
| Net Interest Income | $673,000,000 | $656,200,000 | $422,900,000 | $100,700,000 |
| Interest Income | $716,800,000 | $711,400,000 | $495,900,000 | $160,100,000 |
| Normalized Income | $3,796,958,845 | $4,396,629,377 | $4,379,402,500 | $4,556,917,100 |
| Net Income From Continuing And Discontinued Operation | $4,504,900,000 | $4,412,600,000 | $3,953,600,000 | $4,338,400,000 |
| Total Operating Income As Reported | $3,577,900,000 | $3,990,700,000 | $4,047,100,000 | $4,738,900,000 |
| Net Income Common Stockholders | $4,504,900,000 | $4,412,600,000 | $3,953,600,000 | $4,338,400,000 |
| Net Income | $4,504,900,000 | $4,412,600,000 | $3,953,600,000 | $4,338,400,000 |
| Net Income Including Noncontrolling Interests | $4,504,900,000 | $4,412,600,000 | $3,953,600,000 | $4,338,400,000 |
| Net Income Continuous Operations | $4,504,900,000 | $4,412,600,000 | $3,953,600,000 | $4,338,400,000 |
| Pretax Income | $5,230,700,000 | $4,779,900,000 | $4,199,300,000 | $4,858,800,000 |
| Special Income Charges | $-124,100,000 | $-101,000,000 | $-186,100,000 | $-255,100,000 |
| Interest Income Non Operating | $716,800,000 | $711,400,000 | $495,900,000 | $160,100,000 |
| Operating Income | $3,702,000,000 | $3,990,700,000 | $4,047,100,000 | $4,738,900,000 |
| Gross Profit | $12,242,200,000 | $12,231,500,000 | $11,301,400,000 | $10,612,500,000 |
| Per Share | ||||
| Diluted EPS | $41.48 | $38.34 | $34.77 | $38.22 |
| Basic EPS | $43.07 | $40.90 | $37.05 | $40.51 |
| Other | ||||
| Tax Effect Of Unusual Items | $114,058,845 | $1,329,377 | $-26,697,500 | $-26,182,900 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $4,996,200,000 | $5,300,700,000 | $5,145,800,000 | $5,504,300,000 |
| Total Unusual Items | $822,000,000 | $17,300,000 | $-452,500,000 | $-244,700,000 |
| Total Unusual Items Excluding Goodwill | $822,000,000 | $17,300,000 | $-452,500,000 | $-244,700,000 |
| Reconciled Depreciation | $543,700,000 | $482,900,000 | $421,000,000 | $341,400,000 |
| EBITDA (Bullshit earnings) | $5,818,200,000 | $5,318,000,000 | $4,693,300,000 | $5,259,600,000 |
| EBIT | $5,274,500,000 | $4,835,100,000 | $4,272,300,000 | $4,918,200,000 |
| Diluted Average Shares | $108,600,000 | $115,100,000 | $113,700,000 | $113,500,000 |
| Basic Average Shares | $104,600,000 | $107,900,000 | $106,700,000 | $107,100,000 |
| Diluted NI Availto Com Stockholders | $4,504,900,000 | $4,412,600,000 | $3,953,600,000 | $4,338,400,000 |
| Tax Provision | $725,800,000 | $367,300,000 | $245,700,000 | $520,400,000 |
| Other Special Charges | $124,100,000 | $101,000,000 | $186,100,000 | $255,100,000 |
| Gain On Sale Of Security | $946,100,000 | $118,300,000 | $-266,400,000 | $10,400,000 |
| Research And Development | $5,850,200,000 | $5,233,000,000 | $4,625,100,000 | $3,847,600,000 |
| Selling General And Administration | $2,700,000,000 | $2,954,400,000 | $2,631,300,000 | $2,115,900,000 |
| Restructuring And Mergern Acquisition | - | - | $186,100,000 | $255,100,000 |
Fetched: 2026-05-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $29,999,500,000 | $28,205,000,000 | $24,934,500,000 | $21,748,500,000 |
| Total Assets | $40,558,700,000 | $37,759,400,000 | $33,080,200,000 | $29,214,500,000 |
| Total Non Current Assets | $22,536,800,000 | $19,098,500,000 | $13,601,000,000 | $13,330,400,000 |
| Other Non Current Assets | $1,821,200,000 | $1,136,000,000 | $444,100,000 | $336,400,000 |
| Non Current Deferred Assets | $4,077,200,000 | $3,314,100,000 | $2,575,400,000 | $1,723,700,000 |
| Non Current Deferred Taxes Assets | $4,077,200,000 | $3,314,100,000 | $2,575,400,000 | $1,723,700,000 |
| Investmentin Financial Assets | $10,260,600,000 | $8,900,100,000 | $5,396,500,000 | $6,591,800,000 |
| Goodwill And Other Intangible Assets | $1,257,400,000 | $1,148,600,000 | $1,038,600,000 | $915,500,000 |
| Other Intangible Assets | $1,257,400,000 | $1,148,600,000 | $1,038,600,000 | $915,500,000 |
| Current Assets | $18,021,900,000 | $18,660,900,000 | $19,479,200,000 | $15,884,100,000 |
| Other Current Assets | $474,800,000 | $349,200,000 | $386,600,000 | $411,200,000 |
| Inventory | $3,200,800,000 | $3,087,300,000 | $2,580,500,000 | $2,401,900,000 |
| Receivables | $5,741,100,000 | $6,211,900,000 | $5,667,300,000 | $5,328,700,000 |
| Accounts Receivable | $5,741,100,000 | $6,211,900,000 | $5,667,300,000 | $5,328,700,000 |
| Cash Cash Equivalents And Short Term Investments | $8,605,200,000 | $9,012,500,000 | $10,844,800,000 | $7,742,300,000 |
| Cash And Cash Equivalents | $3,118,100,000 | $2,488,200,000 | $2,730,000,000 | $3,105,900,000 |
| Current Deferred Assets | - | - | - | $521,800,000 |
| Prepaid Assets | - | - | - | $411,200,000 |
| Debt | ||||
| Total Debt | $2,705,900,000 | $2,704,400,000 | $2,702,900,000 | $2,701,400,000 |
| Long Term Debt And Capital Lease Obligation | $2,705,900,000 | $2,704,400,000 | $2,702,900,000 | $2,701,400,000 |
| Long Term Debt | $1,985,900,000 | $1,984,400,000 | $1,982,900,000 | $1,981,400,000 |
| Current Debt And Capital Lease Obligation | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,301,800,000 | $8,405,800,000 | $7,107,100,000 | $6,550,500,000 |
| Total Non Current Liabilities Net Minority Interest | $4,933,400,000 | $4,461,500,000 | $3,683,700,000 | $3,409,200,000 |
| Other Non Current Liabilities | $2,018,800,000 | $1,571,400,000 | $854,100,000 | $638,000,000 |
| Non Current Deferred Liabilities | $208,700,000 | $185,700,000 | $126,700,000 | $69,800,000 |
| Current Liabilities | $4,368,400,000 | $3,944,300,000 | $3,423,400,000 | $3,141,300,000 |
| Current Deferred Liabilities | $553,000,000 | $627,700,000 | $458,900,000 | $477,900,000 |
| Payables And Accrued Expenses | $3,815,400,000 | $3,316,600,000 | $2,964,500,000 | $2,663,400,000 |
| Payables | $1,290,300,000 | $1,002,700,000 | $618,300,000 | $589,200,000 |
| Total Tax Payable | $351,300,000 | $213,200,000 | $11,700,000 | $300,000 |
| Income Tax Payable | $351,300,000 | $213,200,000 | $11,700,000 | $300,000 |
| Accounts Payable | $939,000,000 | $789,500,000 | $606,600,000 | $589,200,000 |
| Equity | ||||
| Common Stock Equity | $31,256,900,000 | $29,353,600,000 | $25,973,100,000 | $22,664,000,000 |
| Total Equity Gross Minority Interest | $31,256,900,000 | $29,353,600,000 | $25,973,100,000 | $22,664,000,000 |
| Stockholders Equity | $31,256,900,000 | $29,353,600,000 | $25,973,100,000 | $22,664,000,000 |
| Gains Losses Not Affecting Retained Earnings | $77,500,000 | $-7,900,000 | $-80,900,000 | $-238,800,000 |
| Other Equity Adjustments | $77,500,000 | $-7,900,000 | $-80,900,000 | $-238,800,000 |
| Retained Earnings | $35,797,100,000 | $31,672,900,000 | $27,260,300,000 | $23,306,700,000 |
| Other | ||||
| Treasury Shares Number | $33,700,000 | $28,200,000 | $25,500,000 | $22,600,000 |
| Ordinary Shares Number | $105,717,146 | $109,617,146 | $109,418,146 | $109,600,000 |
| Share Issued | $139,417,146 | $137,817,146 | $134,918,146 | $132,200,000 |
| Tangible Book Value | $29,999,500,000 | $28,205,000,000 | $24,934,500,000 | $21,748,500,000 |
| Invested Capital | $33,242,800,000 | $31,338,000,000 | $27,956,000,000 | $24,645,400,000 |
| Working Capital | $13,653,500,000 | $14,716,600,000 | $16,055,800,000 | $12,742,800,000 |
| Capital Lease Obligations | $720,000,000 | $720,000,000 | $720,000,000 | $720,000,000 |
| Total Capitalization | $33,242,800,000 | $31,338,000,000 | $27,956,000,000 | $24,645,400,000 |
| Treasury Stock | $18,612,800,000 | $15,167,400,000 | $12,560,400,000 | $10,353,300,000 |
| Additional Paid In Capital | $13,995,000,000 | $12,855,900,000 | $11,354,000,000 | $9,949,300,000 |
| Capital Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Common Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $208,700,000 | $185,700,000 | $126,700,000 | $69,800,000 |
| Long Term Capital Lease Obligation | $720,000,000 | $720,000,000 | $720,000,000 | $720,000,000 |
| Current Deferred Revenue | $553,000,000 | $627,700,000 | $458,900,000 | $477,900,000 |
| Current Accrued Expenses | $2,525,100,000 | $2,313,900,000 | $2,346,200,000 | $2,074,200,000 |
| Investments And Advances | $10,260,600,000 | $8,900,100,000 | $5,396,500,000 | $6,591,800,000 |
| Available For Sale Securities | $10,260,600,000 | $8,900,100,000 | $5,396,500,000 | $6,591,800,000 |
| Net PPE | $5,120,400,000 | $4,599,700,000 | $4,146,400,000 | $3,763,000,000 |
| Accumulated Depreciation | $-2,614,300,000 | $-2,286,900,000 | $-1,978,800,000 | $-1,669,200,000 |
| Gross PPE | $7,734,700,000 | $6,886,600,000 | $6,125,200,000 | $5,432,200,000 |
| Leases | $174,400,000 | $154,500,000 | $133,900,000 | $114,300,000 |
| Construction In Progress | $1,890,200,000 | $1,721,600,000 | $1,345,000,000 | $980,500,000 |
| Other Properties | $1,543,700,000 | $1,494,500,000 | $1,384,500,000 | $1,315,300,000 |
| Machinery Furniture Equipment | $741,700,000 | $654,600,000 | $555,600,000 | $487,600,000 |
| Buildings And Improvements | $3,105,900,000 | $2,573,200,000 | $2,423,100,000 | $2,270,000,000 |
| Land And Improvements | $278,800,000 | $288,200,000 | $283,100,000 | $264,500,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Inventories | $727,500,000 | $725,700,000 | $522,100,000 | $521,800,000 |
| Finished Goods | $190,200,000 | $139,800,000 | $147,300,000 | $98,600,000 |
| Work In Process | $1,641,600,000 | $1,342,300,000 | $1,121,800,000 | $963,100,000 |
| Raw Materials | $641,500,000 | $879,500,000 | $789,300,000 | $818,400,000 |
| Other Short Term Investments | $5,487,100,000 | $6,524,300,000 | $8,114,800,000 | $4,636,400,000 |
| Current Capital Lease Obligation | - | - | - | $0 |
| Dueto Related Parties Current | - | - | - | $10,500,000 |
Fetched: 2026-05-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $3,765,200,000 | $3,538,900,000 | $3,667,600,000 | $3,398,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $4,978,900,000 | $4,420,500,000 | $4,594,000,000 | $5,014,900,000 |
| Cash Flow From Continuing Operating Activities | $4,978,900,000 | $4,420,500,000 | $4,594,000,000 | $5,014,900,000 |
| Operating Gains Losses | $-946,100,000 | $-118,300,000 | $266,400,000 | $36,800,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,213,700,000 | $-881,600,000 | $-926,400,000 | $-1,616,900,000 |
| Investing Cash Flow | $-629,100,000 | $-2,468,100,000 | $-3,185,100,000 | $-3,784,600,000 |
| Cash Flow From Continuing Investing Activities | $-629,100,000 | $-2,468,100,000 | $-3,185,100,000 | $-3,784,600,000 |
| Capital Expenditure Reported | $-898,400,000 | $-755,900,000 | $-718,600,000 | $-590,100,000 |
| Net Other Investing Changes | - | - | - | $-230,300,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-3,970,700,000 | $-3,632,400,000 | $-2,935,600,000 | $-2,528,500,000 |
| Issuance Of Capital Stock | $635,900,000 | $1,465,300,000 | $1,145,500,000 | $1,519,500,000 |
| Financing Cash Flow | $-3,715,400,000 | $-2,200,500,000 | $-1,790,100,000 | $-1,009,000,000 |
| Cash Flow From Continuing Financing Activities | $-3,715,400,000 | $-2,200,500,000 | $-1,790,100,000 | $-1,009,000,000 |
| Net Other Financing Charges | $-10,300,000 | $-33,400,000 | - | - |
| Cash Dividends Paid | $-370,300,000 | $0 | $0 | - |
| Common Stock Dividend Paid | $-370,300,000 | $0 | $0 | - |
| Net Common Stock Issuance | $-3,334,800,000 | $-2,167,100,000 | $-1,790,100,000 | $-1,009,000,000 |
| Common Stock Issuance | $635,900,000 | $1,465,300,000 | $1,145,500,000 | $1,519,500,000 |
| Other | ||||
| Interest Paid Supplemental Data | $41,600,000 | $52,600,000 | $73,100,000 | $53,700,000 |
| End Cash Position | $3,123,700,000 | $2,489,000,000 | $2,737,800,000 | $3,119,400,000 |
| Beginning Cash Position | $2,489,000,000 | $2,737,800,000 | $3,119,400,000 | $2,898,100,000 |
| Effect Of Exchange Rate Changes | $300,000 | $-700,000 | $-400,000 | $0 |
| Changes In Cash | $634,400,000 | $-248,100,000 | $-381,200,000 | $221,300,000 |
| Common Stock Payments | $-3,970,700,000 | $-3,632,400,000 | $-2,935,600,000 | $-2,528,500,000 |
| Net Investment Purchase And Sale | $587,900,000 | $-1,590,100,000 | $-2,203,800,000 | $-1,937,400,000 |
| Sale Of Investment | $11,546,200,000 | $15,027,300,000 | $9,442,200,000 | $5,550,500,000 |
| Purchase Of Investment | $-10,958,300,000 | $-16,617,400,000 | $-11,646,000,000 | $-7,487,900,000 |
| Net Business Purchase And Sale | $-3,300,000 | $-16,500,000 | $-54,900,000 | $-230,300,000 |
| Purchase Of Business | $-3,300,000 | $-16,500,000 | $-54,900,000 | $-230,300,000 |
| Net Intangibles Purchase And Sale | $-315,300,000 | $-125,700,000 | $-207,800,000 | $-1,026,800,000 |
| Purchase Of Intangibles | $-315,300,000 | $-125,700,000 | $-207,800,000 | $-1,026,800,000 |
| Net PPE Purchase And Sale | $0 | $20,100,000 | $0 | $0 |
| Sale Of PPE | $0 | $20,100,000 | $0 | $0 |
| Change In Working Capital | $532,600,000 | $-618,300,000 | $-94,100,000 | $-243,300,000 |
| Change In Other Working Capital | $-51,700,000 | $227,800,000 | $37,900,000 | $32,400,000 |
| Change In Payables And Accrued Expense | $736,800,000 | $735,100,000 | $598,600,000 | $-138,400,000 |
| Change In Payable | $736,800,000 | $735,100,000 | $598,600,000 | $-138,400,000 |
| Change In Account Payable | $736,800,000 | $735,100,000 | $598,600,000 | $-138,400,000 |
| Change In Prepaid Assets | $-375,300,000 | $-407,500,000 | $-120,100,000 | $-148,600,000 |
| Change In Inventory | $-275,300,000 | $-619,700,000 | $-271,700,000 | $-696,500,000 |
| Change In Receivables | $498,100,000 | $-554,000,000 | $-338,800,000 | $707,800,000 |
| Changes In Account Receivables | $498,100,000 | $-554,000,000 | $-338,800,000 | $707,800,000 |
| Other Non Cash Items | $135,500,000 | $36,100,000 | $-100,000 | $563,000,000 |
| Stock Based Compensation | $993,700,000 | $982,800,000 | $885,000,000 | $725,000,000 |
| Deferred Tax | $-785,400,000 | $-757,300,000 | $-837,800,000 | $-746,400,000 |
| Deferred Income Tax | $-785,400,000 | $-757,300,000 | $-837,800,000 | $-746,400,000 |
| Depreciation Amortization Depletion | $543,700,000 | $482,900,000 | $421,000,000 | $341,400,000 |
| Depreciation And Amortization | $543,700,000 | $482,900,000 | $421,000,000 | $341,400,000 |
| Gain Loss On Investment Securities | $-946,100,000 | $-118,300,000 | $266,400,000 | $36,800,000 |
| Net Income From Continuing Operations | $4,504,900,000 | $4,412,600,000 | $3,953,600,000 | $4,338,400,000 |
| Income Tax Paid Supplemental Data | - | $743,000,000 | $870,300,000 | $1,502,400,000 |
| Amortization Cash Flow | - | $128,900,000 | $92,200,000 | $37,600,000 |
| Amortization Of Intangibles | - | $128,900,000 | $92,200,000 | $37,600,000 |
| Depreciation | - | $354,100,000 | $328,800,000 | $303,900,000 |
| Repayment Of Debt | - | - | - | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-05-23